Presentation on theme: "Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total."— Presentation transcript:
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total Occlusion
SICTO STUDY DESIGN A multicenter, prospective, non-randomized study to assess the feasibility and restenosis/reocclusion rates of coronary stenting with the Cypher TM Sirolimus-eluting stent in patients with chronic total occlusion - 25 patients were treated with the Cypher TM Sirolimus- eluting stent after successful balloon angioplasty and IVUS examination. - Clinical follow-up at 30 days, 6, 12, 18 and 24 months - repeat angiography and IVUS at 6 months follow-up.
Main complaint: severe shortness of breath and chest pain on mild exertion, increasing over last 6 months Risk factors: Hyperlipidemia (10 y), DM (25y), HTN 66 year-old female Coronary angiography revealed diffusely diseased extremely small coronary arteries with a proximal occlusion in the LAD (arrow) Case from SICTO Study
Baseline Post procedure 6 mos. follow-up Patient underwent successful recanalization of the LAD with implantation of 2 long Cypher stents (2.5/23). Patient’s condition improved significantly after procedure and returned to functional Class I. Despite very long lesion (2 stents) in a very diffuse small artery, 6 months follow-up shows stents are widely patent. Chaim Lotan MD Hadassah-Hebrew University Medical Center, Jerusalem Israel
SICTO – Conclusion In this feasibility study the CYPHER TM Sirolimus- eluting stent was very effective in the treatment of CTO, with very low rates of TLR (0%), MACE (0%) and TVR (8%) compared to historical data with bare stents (30-50%). The CYPHER TM Sirolimus-eluting stent significantly inhibits intimal hyperplasia in CTO. These preliminary data will come in addition of larger database with CTO subpopulation (e.g. e- Cypher)